M edulloblastoMas are invasive embryonal tu mors of the posterior fossa and represent the most frequent malignant tumor of the CNS in childhood. They comprise between 15% and 20% of all childhood brain tumors. 2, 7, 18 The rate of recurrence of pe diatric medulloblastoma is between 35% and 40%.
Operation and Postoperative Course. A grosstotal resection was performed 2 days later and the histological diagnosis of medulloblastoma was confirmed. Pathologi cal analysis demonstrated a small, round, bluecell tumor with neuronal differentiation, which despite extensive re ticulin deposition, did not show the nodular pattern of the classic nodular/desmoplastic variant. After initial resec tion she developed posterior fossa syndrome that slowly resolved. On postdischarge followup, she was noted to have a rightsided hand and arm tremor and dysconjugate gaze, but was ambulating well. The patient later received radiation and chemotherapy according to the Children's Oncology Group protocol (ACNS0331). She received a total of 23.40 Gy of cranial spine radiation therapy, fol lowed by a posterior fossa boost of 30.60 Gy. Chemother apy included vincristine, cisplatin, cyclophosphamide, lo mustine, and supportive medications.
Second Presentation. The patient first presented to ophthalmology 6 months after initial presentation and treatment; at that time she demonstrated 20/20 vision in both eyes, and a mild palsy of the sixth cranial nerve. She Misdiagnosing recurrent medulloblastoma: the danger of examination and imaging without histological confirmation The screening and detection of recurrent medulloblastoma presents the clinician with significant diagnostic chal lenges, including the risk of misdiagnosis. The authors present the case of a young girl with a history of a treated stan dardrisk medulloblastoma that highlights the risk of assuming recurrence has occurred when clinical and/or imaging changes are observed. This girl developed both new clinical deficits and had radiographic evidence of recurrence. She subsequently experienced a complete resolution of symptoms and radiographic findings with steroids alone. had no afferent pupillary defect and the rest of her exami nation was normal.
The patient's treatment course was complicated by a persistent strabismus, weight loss greater than 10%, hear ing deficits secondary to ototoxicity, chemotherapy delay secondary to thrombocytopenia, foot drop, and depression. She attended school and received occupational and physi cal therapy at a rehabilitation center. Treatment with che motherapy was completed 1 year after initial diagnosis; it was stopped 2 cycles early due to her mother's request.
Fourteen months after her last therapy, at 9 years of age, the patient presented for an urgent reevaluation. At that time, the mother noted her eyes "did not seem right," and her teachers noted that she was not writing on the lines and was writing off of the page. Upon review of the patient's systems, she was found to have experienced 2 weeks of increased fatigue and some decreased strength of the right arm. She underwent urgent evaluation by pe diatric ophthalmology and was noted to have an acute change in vision; her visual acuity had dropped to 20/200 in the right eye and 20/400 in the left eye. The rest of her examination was completely normal, including a resolu tion of her sixth cranial nerve palsy.
An emergency MR image revealed multiple areas of enhancement that appeared to be recurrent disease (Figs.  2 and 3 ). An MR image of the spine revealed clumping of nerve roots in the lumbar spine as may be noted with lepto meningeal disease. The differential diagnosis included re current medulloblastoma, radiation myelitis, viral myelitis, Lyme disease, demyelinating disease, or sarcoidosis.
The family declined lumbar puncture and biopsy. Our plan would have been to treat the disease if biopsy and/or lumbar puncture were positive and observe clini cally and with repeat imaging if the biopsy was negative or inconclusive. The family also did not wish to seek any further tumor control therapy and the patient was pre scribed dexamethasone for symptomatic relief. Palliative care and hospice options were discussed.
Later Course. Over the next 4 months the dexa methasone was weaned and the patient was noted to have clinical improvement; her vision improved, she was less fatigued, more active, able to ambulate on her own, read, and attend school. On ophthalmological examination 8 months following her presumed recurrence, she was found to have 20/20 vision in both eyes and a new affer ent pupillary defect in the left eye. Optical coherence to mography revealed significant nerve fiber layer loss in the retina, consistent with optic neuropathy that was likely due to the acute visual event at the time of intracranial findings suggesting recurrence. Her dilated funduscopic examination revealed mild pallor of both optic nerves, also a sign of previous optic neuropathy. All these find ings suggested a previous process that had affected both optic nerves.
Repeat MRI conducted 4 months after the presumed recurrence showed stable postoperative change and white matter signal abnormalities, but did not demonstrate any abnormal enhancement or leptomeningeal disease. The overall study appeared improved in comparison with the prior study. At her most recent ophthalmological follow up, 2 years and 8 months after her presumed recurrence, she was noted to have maintained her 20/20 vision and the rest of her examination was unchanged.
Discussion
In the case described, the clinical team was faced with a 10yearold girl with medulloblastoma who pre sented with a visual deficit and new lesion, but left with out the capacity to histologically confirm the diagnosis. The case raises important questions. What is the best way to screen for recurrent disease? Can recurrent disease be diagnosed based on clinical and MRI findings alone, or do we need histological confirmation? What differential diagnosis must be considered?
While the radiographic changes in our patient were not found on surveillance imaging, such a misleading MR image calls into question the utility of routine screening. The rationale behind surveillance imaging is that early detection of tumor recurrence will allow for prompt inter vention and thus improved outcome. However, multiple studies have shown that surveillance scanning detected only a minority of recurrences and brought no survival advantage. 1, 27, 29 One such study found no statistical differ ence in the survival rate between patients with symptom atic recurrence and those with an asymptomatic recur rence detected as part of surveillance screening. 27 The survival advantage of early detection may be lim ited by our ability to successfully treat recurrent disease. Patients with recurrent medulloblastoma following mul timodal therapy typically have tumors that are incurable despite further treatment. Salvage chemotherapy regi mens, including alkylatorbased highdose chemotherapy with stem cell rescue, have been used to treat recurrent disease without significantly improved outcome. 8, 13, 22 Newer, targeted therapies aimed at antiangiogenesis and other molecular pathways implicated in medulloblastoma are presently being studied. The current Children's On cology Group study for recurrent/refractory medulloblas toma (ACNS0821) is a Phase II randomized trial compar ing the effectiveness of the combination of irinotecan and temozolomide with that of the same drugs combined with bevacizumab. 11 Despite the lack of an established, effec tive salvage therapy, 1 advantage, as suggested by Shaw and colleagues, 21 is that early detection of relapse with minimum disease may provide the best setting in which to test newer therapies.
Regardless of the lack of definitive evidence on its utility, current protocols not only employ surveillance scanning to detect recurrent disease, but also do not re quire histological confirmation. In the ACNS0821 pro tocol, the study authors define disease as tumor that is measurable in 2 perpendicular diameters on MRI and state that the patient must have had histological verifica tion of the malignancy at original diagnosis or, but not necessarily, at the time of recurrence. Likewise, in the current Pediatric Brain Tumor Consortium Phase II study (PBTC-032) on recurrent/refractory medulloblastoma, the patients must only have bidimensionally measurable disease in the brain or spinal cord, defined as at least 1 lesion that can be accurately measured in at least 2 planes (PBTC-032).
Radiographic findings found on either routine or emergency imaging must be interpreted with caution. Clinicians must question if recurrent disease can be dif ferentiated from treatmentinduced changes, or pseudo progression, on MRI. Abnormal findings following ra diation therapy have been widely documented on MRI in children treated for brain tumors. 5, 24 There is also evidence to suggest that standard or highdose chemo therapy can injure the normal brain, 9 and there appears to be a compounding effect when radiation therapy and che motherapy are used together. 3, 14, 15, 17, 20 In a Phase I/II study evaluating the use of carboplatin during radiation therapy in patients with medulloblastoma, the authors found 4 metastatic patients with early progression of leptome ningeal disease who were longterm survivors following palliative chemotherapy alone. The authors, in retrospect, stated that these patients were not believed to have true progressive disease. 15 Additionally, there is increased evidence of clini cal and radiographic therapyrelated alterations as a re sult of the more frequent use of highdose chemotherapy combined with radiation therapy for pediatric brain tu mors. 16, 25 Our patient was observed to have clinical symp toms and radiographic changes more than a year after therapy. It is important to note that radiation-induced MRI abnormalities can occur even a significant time after therapy. Spreafico and colleagues 25 found that of the 49 children with malignant brain tumors, 18 had abnormal brain MRI findings occurring at a median of 8 months, but for as long as 39 months, after radiation therapy (6 of 25 with highgrade gliomas and 12 of 24 with primitive neuroectodermal tumors). Furthermore, as in our patient, they found that onehalf of the patients had symptoms re lating to the new radiographic findings. the tumor bed (A), corpus callosum (B), and subcortical white matter (C-E) .
Fig. 3. Axial MRI FLAIR image demonstrating abnormal signal in the corpus callosum splenium (arrows).
Our patient also had evidence of leptomeningeal dis ease, both clinically and radiographically. Previous stud ies have shown that MRI of the brain and spine with a T1weighted Gdenhanced sequence is the standard and most sensitive way to detect leptomeningeal disease on neuroimaging. 23 This raises the question of whether the presence of typical clinical features, in conjunction with appropriate neuroimaging abnormalities, is adequate to make the diagnosis of leptomeningeal disease even if CSF cytological results are negative.
In their review, Taillibert and colleagues 26 stated that the most accurate way to diagnose recurrent leptomenin geal disease was by lumbar puncture, with detection of malignant cells being the most important finding. Howev er, the initial cytology may be falsely negative in a signifi cant proportion of cases. 12, 19, 28 Prior studies in adults have shown that repeated sampling can significantly enhance the diagnostic yield. Therefore, in adults, some have rec ommended performing at least 3 lumbar punctures over several days if the initial cytology is negative. 12, 28 Lumbar puncture may also be essential to differenti ate leptomeningeal disease from infectious and inflamma tory causes of subacute and chronic meningitis because they can produce similar images on MRI. For example, Fouladi and colleagues 10 presented a case of a 16yearold boy whose medulloblastoma had been successfully treat ed and underwent MRI that demonstrated asymptomatic nodular leptomeningeal enhancement of the brain and spinal cord, consistent with recurrent disease. Examina tion of the CSF, however, led to the diagnosis of bacterial meningitis, and after completing 2 weeks of antibiotic therapy, the findings on the original MRI resolved. The authors caution that even though nodular leptomeningeal enhancement is more commonly observed in neoplastic disease than infectious meningitis, it is imperative to con sider all clinical and laboratory data, including results from a complete examination of the CSF, when interpret ing the origin of new lesions revealed by MRI.
Even though they are rare, second tumors due to ra diation therapy must also be considered. We know that pe diatric patients with primary malignant brain tumors who received radiation therapy have an increased risk of devel oping a secondary malignant neoplasm, the majority of which are brain tumors and include meningioma, glioblas toma, and anaplastic astrocytoma. 4, 6 Studies have shown a high rate of mortality associated with secondary gliomas, but a high survival rate of secondary meningiomas. 4 The utility of screening for recurrent medulloblasto ma remains controversial, especially in the absence of es tablished effective salvage therapies; however, as current protocols still recommend routine surveillance scanning, the physician must be prepared to critically interpret posi tive results. As we have illustrated, caution must be taken when basing the diagnosis of recurrent medulloblastoma on symptomatology and MRI alone. While the differ ential diagnosis may be less common than tumor recur rence, it is important to consider the implications of a false positive finding on clinical or radiographic examination. Clinical trials do not require histological confirmation of recurrence, and therefore resolution of pseudoprogression may be interpreted as treatment response. For the patient, the risks associated with further neurosurgery, which are small with current techniques, may not outweigh the ben efits of confirming recurrence. Furthermore, there exists the possibility of finding a more treatable condition, such as infection, or a secondary malignancy, such as a menin gioma, which may have a good prognosis compared with recurrent disease.
